Soen, Satoshi
Yamamoto, Kazuhiko
Takeuchi, Tsutomu
Tanaka, Yoshiya
Tanaka, Sakae
Ito, Masako
Nakano, Tetsuo
Hagino, Hiroshi
Hirakawa, Akihiro
Matsumoto, Toshio
Funding for this research was provided by:
Astellas Pharma
Ono Pharmaceutical (None)
Article History
Received: 6 August 2019
Accepted: 17 December 2019
First Online: 22 January 2020
Compliance with ethical standards
:
: S.S. has received consulting fees, speaking fees, and/or honoraria from Asahi Kasei Pharma, Astellas, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly Japan, MSD, Ono, Pfizer, Takeda and Teijin Pharma. K.Y. has received speaking fees, and/or honoraria from AbbVie, Astellas, AYUMI Pharma, Bristol-Myers Squibb, Chugai, Eisai, Janssen, Mitsubishi-Tanabe, Ono and UCB Japan. T.T. has received grants from Astellas, Chugai, Daiichi-Sankyo, Takeda, AbbVie, Asahi kasei Pharma., Mitsubishi-Tanabe, Pfizer, Eisai, AYUMI Pharma, Nipponkayaku., Novartis and Shionogi. Personal Fee from: Astellas, AbbVie, AYUMI Pharma, Eisai., Gilead Sciences, GlaxoSmithKline, Sanofi., Taiho, Mitsubishi-Tanabe, Diaichi-Sankyo, Chugai, Taisho Pharma, Eli Lilly Japan, Novartis, Boehringer-ingelheim, Nipponkayaku, Pfizer、Bristol–Myers Squibb, Janssen and UCB Japan. Y.T. has received speaking fees and/or honoraria from Daiichi-Sankyo, Astellas, Chugai, Eli Lilly Japan, Pfizer, AbbVie, YL Biologics, Bristol-Myers Squibb, Takeda, Mitsubishi-Tanabe, Novartis, Eisai, Janssen, Teijin Pharma and has received research grants from Asahi kasei Pharma, Mitsubishi-Tanabe, Chugai, Takeda, Sanofi, Bristol-Myers Squibb, UCB Japan, Daiichi-Sankyo, Eisai and Ono. S.T. has received consulting fees, speaking fees, and/or honoraria from Amgen Astellas Biopharma, Astellas, Asahi Kasei Pharma, Chugai, Daiichi-Sankyo, Eisai, Eli Lilly Japan, Ono, Pfizer, Taisho Toyama Pharma and Teijin Pharma. M.I. has received consulting fees, speaking fees, honoraria, and/or research funding from Chugai, Astellas, Asahi Kasei Pharma, Daiichi-Sankyo, Eli Lilly Japan, MSD, Ono and Pfizer. H.H. has received lecture fees or grants from Asahi Kasei Pharma, Astellas, Chugai, Eisai, Eli Lilly Japan, Mitsubishi -Tanabe, Mochida, Ono, Pfizer, Taisho Toyama, Takeda, Teijin Pharma, MSD and UCB. A.H. has received consulting fees, speaking fees, honoraria, and/or research funding from Astellas, Ono and Teijin Pharma. T.M. has received consulting fees from Chugai, Amgen Astellas Biopharma, Teijin Pharma, Daiichi-Sankyo and Asahi Kasei Pharma.